A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Dexmedetomidin – Pharmacokinetics and pharmacodynamics
Alaotsikko: Pharmacokinetics and pharmacodynamics
Tekijät: Ihmsen H, Saari TI
Kustantaja: SPRINGER
Julkaisuvuosi: 2012
Journal: Anaesthesist
Tietokannassa oleva lehden nimi: ANAESTHESIST
Lehden akronyymi: ANAESTHESIST
Vuosikerta: 61
Numero: 12
Aloitussivu: 1059
Lopetussivu: 1066
Sivujen määrä: 7
ISSN: 0003-2417
DOI: https://doi.org/10.1007/s00101-012-2114-1
Tiivistelmä
Dexmedetomidine is a highly selective, potent alpha(2)-adrenoceptor agonist which was approved in 2011 by the European Medicines Agency for sedation of patients in intensive care units (ICU). Dexmedetomidine exhibits sedative as well as analgesic and anxiolytic effects. Recent studies suggest that dexmedetomidine may be an alternative to midazolam in long-term ICU sedation. This review summarizes the pharmacokinetics and pharmacodynamics of dexmedetomidine particularly in ICU patients and with special regard to covariate effects. Although dexmedetomidine is currently approved only for use in adults the pharmacokinetics and pharmacodynamics in children will also be addressed as there are numerous studies on this off-label use.
Dexmedetomidine is a highly selective, potent alpha(2)-adrenoceptor agonist which was approved in 2011 by the European Medicines Agency for sedation of patients in intensive care units (ICU). Dexmedetomidine exhibits sedative as well as analgesic and anxiolytic effects. Recent studies suggest that dexmedetomidine may be an alternative to midazolam in long-term ICU sedation. This review summarizes the pharmacokinetics and pharmacodynamics of dexmedetomidine particularly in ICU patients and with special regard to covariate effects. Although dexmedetomidine is currently approved only for use in adults the pharmacokinetics and pharmacodynamics in children will also be addressed as there are numerous studies on this off-label use.
Turun yliopiston Tutkimustietojärjestelmän portaali